Immatics Biotechnologies has teamed up with University of Texas MD Anderson Cancer Center to set up Immatics US and develop treatments for tumours.
Germany-based biopharmaceutical company Immatics Biotechnologies has established a US-based spinout dubbed Immatics US with more than $40m in funding, Fierce Biotech reported on Tuesday.
The company has also secured a $19.7m grant from the Cancer Prevention and Research Institute of Texas, an organisation set up and funded by the Texas state government.
Immatics US will develop three adoptive cellular therapies (ACTs) by collaborating with Patrick Hwu and Cassian Yee from University of Texas MD Anderson Cancer Center. The company has…
